. How monoclonal antibodies work against omicron variant « JO LEE MAGAZINE

ABC NEWS – The first oral antiviral treatments for the virus were authorized by the Food and Drug Administration this week: Pfizer’s Paxlovid, and Merck’s Molnupiravir, which have proved effective against severe illness and death from COVID, and are expected to hold up against omicron. The news lent a glimmer of hope amid the latest surge — but supply is expected to remain limited for months as production ramps up. Meanwhile, omicron’s high transmission rate is squeezing what was already a finite arsenal of COVID medicines. Of the currently authorized monoclonal antibody therapies — which have become a primary means to keep patients out of the hospital.

More at ABC NEWS

World on the Run | Jo Lee Magazine

Comments are closed.